Pharma


  • A computer screen shows the Pfizer logo and stock price at the New York Stock Exchange
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Pfizer expands cost cuts with new $1.5B target

    The company, which previously announced plans to trim $4 billion in spending by the end of 2024, aims to save another $1.5 billion over the next three years.

    By May 22, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Regeneron faces new biosimilar threats; an AI biotech lays off staff

    Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers. 

    By BioPharma Dive staff • May 22, 2024
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Explore the Trendline
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    COVID-19 vaccines

    The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.

    By BioPharma Dive staff
  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca’s $80B sales plan leans on cancer drug expansion

    The drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.

    By May 21, 2024
  • Image attribution tooltip
    AstraZeneca
    Image attribution tooltip

    AstraZeneca sets sights on $80B in revenue by 2030

    The U.K. pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.

    By May 21, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Erasca restructures; Novartis moves to complete MorphoSys deal

    The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.

    By BioPharma Dive staff • May 17, 2024
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip
    Obesity drugs

    Roche keeps pace in obesity drug field with early study data

    A drug Roche acquired in a buyout of Carmot Therapeutics and that works similarly to Zepbound helped people lose nearly 19% of their body weight in a Phase 1 trial.

    By May 16, 2024
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to buy Proteologix and its dual-targeting antibody drugs for $850M

    The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development. 

    By Kristin Jensen • May 16, 2024
  • Image attribution tooltip
    Andreas Rentz via Getty Images
    Image attribution tooltip

    Bayer details layoffs as company shake-up continues

    The reduction of 1,500 roles in the first quarter is part of CEO Bill Anderson’s plan to shrink Bayer’s bureaucracy and “radically realign” its culture.

    By May 14, 2024
  • Close up of test tubes
    Image attribution tooltip
    deliormanli via Getty Images
    Image attribution tooltip
    Sponsored by Almac Group

    Partnering for success: Choosing the right CDMO in pharma outsourcing

    Explore the four most important qualities for choosing a dependable outsourcing partner in pharma.

    May 13, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    iTeos shares jump on TIGIT update; Acelyrin swaps CEOs

    Interim data surpassed expectations, iTeos said. Bluebird bio, meanwhile, gave a fuller accounting of launch progress for its gene therapies Lygenia, Zynteglo and Skysona. 

    By BioPharma Dive staff • May 10, 2024
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    RSV vaccines

    FDA delays decision on Moderna RSV vaccine

    The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.

    By May 10, 2024
  • Prepared syringes are lined up in a yellow tray.
    Image attribution tooltip
    Carsten Koall via Getty Images
    Image attribution tooltip

    Novavax gets a lifeline with Sanofi vaccine pact

    Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines.

    By May 10, 2024
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Takeda targets ‘efficiency’ in restructuring, pipeline cuts

    Among the pipeline changes is a decision by Takeda to terminate studies in blood cancer of TAK-007, a CAR-NK therapy, and to pivot instead to autoimmune conditions.

    By Updated May 10, 2024
  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire here.

    Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines.

    By Updated May 13, 2024
  • Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    AstraZeneca withdraws COVID-19 vaccine, citing declining demand

    The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects. 

    By May 8, 2024
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip
    New Alzheimer's drugs

    FDA sets date for advisory meeting on Lilly’s closely watched Alzheimer’s drug

    After delaying an approval decision for Lilly’s donanemab, the agency now intends to hold an advisory committee meeting on June 10.

    By May 7, 2024
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca ups stake in Cellectis in latest cell therapy bet

    The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.

    By May 6, 2024
  • Doctor holding pills bottle in hand with medical icons. Pharmaceutical and health care concept.
    Image attribution tooltip
    PrathanChorruangsak via Getty Images
    Image attribution tooltip
    Sponsored by Worldwide Clinical Trials

    Maximizing efficiency in translational medicine with an on-site pharmacy

    The ability to modify drug formulations in real time and dosage strengths is crucial, while adhering to all regulatory standards and maintaining cGMP standards.

    May 6, 2024
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip
    Obesity drugs

    Amgen shares soar as executives outline obesity drug push

    The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.

    By May 3, 2024
  • A sign reading Novartis is seen on the side of a building viewed through trees.
    Image attribution tooltip
    Novartis
    Image attribution tooltip

    Why selling to Novartis made sense for Mariana

    Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."

    By May 3, 2024
  • Two prescription drug cartons are seen stacked on top of each other, bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo sees Wegovy sales dip on lower price, tight supply

    First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

    By May 2, 2024
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis to buy Mariana Oncology in radiopharmaceutical expansion

    The $1 billion dollar acquisition will add to Novartis’ pipeline of the targeted radiation drugs, giving it a potential lung cancer treatment.

    By May 2, 2024
  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK raises forecasts on strong vaccine, HIV drug sales

    Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.

    By May 1, 2024
  • A chromatic Pfizer sign hangs on a building façade
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

    Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.

    By May 1, 2024
  • A Lilly sign is seen on the side of a building viewed through pine trees
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly counts on manufacturing scale-up to unstick obesity drug supply

    Increasing the production capacity for Zepbound and Mounjaro is “the most ambitious expansion plan in our company’s history,” said CEO David Ricks.

    By April 30, 2024